The role of angiogenesis in human non-Hodgkin lymphomas

Neoplasia. 2013 Mar;15(3):231-8. doi: 10.1593/neo.121962.


The role of angiogenesis in the growth of lymphomas and survival of patients with leukemias and other hematological malignancies has become evident since 1994. Angiogenic factors, such as vascular endothelial growth factor and its receptors together with other tumor microenvironment components, including myelo-monocytic cell, mast cells, endothelial progenitor cells, and circulating endothelial cells, have been shown to be important in the progression and maintenance of lymphoproliferative disorders. In this review article, we present an overview of the literature focusing on the relationship between angiogenesis and disease progression and the recent advantages in the antiangiogenic treatment in human non-Hodgkin lymphomas.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Disease Models, Animal
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Humans
  • Lymph Nodes / blood supply
  • Lymphatic Diseases / pathology
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / pathology*
  • Mast Cells / metabolism
  • Mast Cells / pathology
  • Myeloid Cells / metabolism
  • Myeloid Cells / pathology
  • Neovascularization, Pathologic* / drug therapy


  • Angiogenesis Inhibitors